Publications

Mease K, Kimzey A, Lansita J. 2017. Biomarkers for nonclinical infusion reactions in marketed biotherapeutics and considerations for study design. Curr Opin Toxicol 4(June):1–15; doi: 10.1016/j.cotox.2017.03.005.

Thompson CM, Wolf, JC, McCoy A, Suh M, Proctor DM, Kirman CR, Haws LC, Harris MA. 2017. Comparison of toxicity and recovery in the duodenum of B6C3F1 mice following treatment with intestinal carcinogens captan, folpet, and hexavalent chromium. Toxicol Pathol 45(8):1091–1101; doi: 10.1177/019262331yy4324.

Fitzpatrick JM, Roberts DW, Patlewicz G. 2017. What determines skin sensitization potency–Myths, maybes and realities. The 500 molecular weight cut-off – An updated analysis. J Appl Toxicol 37(1):105-116; doi: 10.1002/jat.3348. PMID: 27283458.

Fitzpatrick JM, Roberts DW, Patlewicz G. 2017. Is skin penetration a determining factor in skin sensitization potential and potency? Refuting the notion of a LogKow threshold for skin sensitization. J Appl Toxicol 37(1):117-127; doi: 10.1002/jat.3354. PMID: 27357739.

Thompson CM, Bichteler A, Rager JE, Suh M, Proctor DM, Haws LC, Harris MA. 2016. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium. Mut Res/Genet Toxicol Environ Mutagen 800-801(April):28-34; doi: 10.1016/j.mrgentox.2016.01.008.

Patlewicz G, Casati S, Basketter D, Asturiol D, Roberts DW, Lepoittevin J-P, Aschberger K. 2016. Can currently available non-animal methods detect pre and pro haptens relevant for skin sensitization? Regul Toxicol Pharmacol 82(10):147-155;p doi: 10.1016/j.yrtph.2016.08.007. PMID: 27569201.

Thompson CM, Rager JE, Suh M, Ring CL, Proctor DM, Haws LC, Fry RC, Harris MA. 2016. Transcriptomic responses in the oral cavity of F344 rats and B6C3F1 mice following exposure to Cr(VI): Implications for risk assessment. Environ Molec Mutagen 57:706-716.

De Flora S, Camoirano A, Micale RT, La Maestra S, Savarino V, Zentilin P, Marabotto E, Suh M, Proctor DM. 2016. Reduction of hexavalent chromium by fasted and fed human gastric fluid.  I. Chemical reduction and mitigation of mutagenicity. Toxicol Appl Pharmacol  306:113-119.

Roberts DW, Api AM, Patlewicz G, Schultz TW. 2016. Chemical applicability domain of the Local Lymph Node Assay (LLNA) for skin sensitization potency. Part 1. Underlying physical organic chemistry principles and the extent to which they are represented in the LLNA validation dataset. Regul Toxicol Pharmacol 80(Oct):247-254; doi: 10.1016/j.yrtph.2016.07.007. PMID: 27424000.

Richard A, Judson R, Houck K, Grulke C, Volarath P, Thillainadarajah I, Yang C,…, Patlewicz G, et al. 2016. The ToxCast chemical landscape: Paving the road to 21st century toxicology. Chem Res Toxicol 29(8):1225-1251; doi: 10.1021/acs.chemrestox.6b00135. PMID: 27367298.